Search Results
Mar 05, 2026, 23:53 ET 全球首個偏向型GLP-1減重藥物先維盈®獲批上市
View original content:https://www.prnewswire.com/apac/zh/news-releases/glp-1-302706332.htmlSOURCE 杭州先為達生物科技股份有限公司
More news about: 杭州先為達生物科技股份有限公司
Mar 05, 2026, 16:03 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Mar 05, 2026, 13:03 ET Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company's Integrated Sacral Neuromodulation System for Urinary Urge Incontinence
battery-related revision surgeries; these battery-related issues may become more frequent with weight loss associated with widespread GLP-1 agonist use. As anticipated, the Neuspera SNM System maintained an excellent safety profile, with zero serious device-related adverse events (AEs)
More news about: Neuspera Medical
Mar 05, 2026, 10:01 ET North American Dietary Supplements Market Poised to Add USD 90.4B by 2036 - Future Market Insights (FMI)
retail intermediaries.3) GLP-1 weight management creates a 'nutrient-gap' adjacency wave.GLP-1 receptor agonist adoption is generating
More news about: Future Market Insights
Mar 05, 2026, 09:01 ET More Than Half of GLP-1 Users Reported Seeking Follow-Up Care for Side Effects, Phenomix Sciences Report Finds
medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care.Real-world response varies: Many GLP-1 users reported variability in outcomes,
More news about: Phenomix Sciences
Mar 05, 2026, 06:00 ET Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
(OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known whether Zepbound is safe and effective for use in children.Zepbound is available in 2.5 mg, 5
More news about: Eli Lilly and Company
Mar 04, 2026, 13:59 ET Transactional Messages Deliver Outsized Revenue Impact, Listrak's 2026 Beauty & Fashion Benchmark Report Reveals
luxury assortments while increasing promotional intensity to retain value-focused shoppers.GLP-1s Reshaping Inventory: With over 12% of Americans reported to be using GLP-1 medications and obesity rates declining, apparel retailers are adjusting size curves and inventory allocation
More news about: LISTRAK
Mar 04, 2026, 13:16 ET DIA 2026 Global Annual Meeting Reimagines the World's Leading Life Sciences Forum
each day will have a plenary, with topics including patient-driven science and AI-powered discovery, the scientific and policy journey behind GLP-1 obesity therapies, the evolution of advanced cell therapy, and the forces reshaping healthcare's future. The redesigned program includes 10 refreshed
More news about: Drug Information Association
Mar 04, 2026, 09:07 ET ISSA Named Exclusive Global Education Partner for cult.fit
As part of the initial rollout, 750 cult.fit fitness professionals will complete ISSA's GLP-1 Weight Loss Support Training program, gaining evidence-based education in metabolic health, GLP-1 medications, and responsible client coaching. The partnership establishes a single, science-backed
More news about: International Sports Sciences Association (ISSA)
Mar 04, 2026, 09:07 ET ISSA Named Exclusive Global Education Partner for cult.fit
part of the initial rollout, 750 cult.fit fitness professionals will complete ISSA's GLP-1 Weight Loss Support Training program, gaining evidence-based education in metabolic health, GLP-1 medications, and responsible client coaching. The partnership establishes a single, science-backed
More news about: International Sports Sciences Association (ISSA)
Mar 04, 2026, 09:07 ET ISSA को cult.fit के लिए विशिष्ट वैश्विक शिक्षा भागीदार नामित किया गया
प्रारंभिक चरण के भाग के रूप में, मेटाबॉलिक स्वास्थ्य, GLP-1 औषधियों और जिम्मेदार ग्राहक कोचिंग में साक्ष्य-आधारित शिक्षा प्राप्त करने के लिए cult.fit के 750 फिटनेस पेशेवर ISSA के GLP-1 Weight Loss Support Training कार्यक्रम को पूरा करेंगे। यह भागीदारी cult.fit के व्यापक
More news about: International Sports Sciences Association (ISSA)
Mar 04, 2026, 08:48 ET Libellula Health Redefines Weight Wellness with Launch of Weight Management Complete Concierge Program in Tucson
TUCSON, Ariz., March 4, 2026 /PRNewswire/ -- As the national conversation around GLP-1 medications reaches a fever pitch, Libellula Health is moving beyond the trend to launch Weight Management Complete. This physician-guided, concierge-style
More news about: Libellula Health
Mar 04, 2026, 08:31 ET MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Mar 04, 2026, 08:31 ET Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
by Day 8 was observed, accompanied by apoptotic signaling consistent with KIT pathway knock-down.Bioanalytical readiness: GLP-validated bioanalytical methods completed to support pharmacokinetic, biodistribution, and exposure-response analyses for IND.HT-KIT
More news about: Hoth Therapeutics, Inc.
Mar 04, 2026, 08:00 ET ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
option, with 81% of HCPs identifying HA fillers as a top nonsurgical modality following GLP-1 related weight lossvii.One-third of physicians (33%) say GLP-1 usage has increased the overall volume of dermal filler injections in their practiceviii.Allergan
More news about: AbbVie
Mar 03, 2026, 17:31 ET Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
also contribute significantly to disease management.In January 2025, the US FDA approved OZEMPIC (semaglutide) as the first GLP-1 receptor agonist indicated to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and CKD.The
More news about: DelveInsight Business Research, LLP
Mar 03, 2026, 14:32 ET Government Expands GLP-1 Access -- Menu-Order-AI Powers Everyday Decision Support
to GLP-1 medications under Medicare and Medicaid through negotiated pricing and structured coverage. GLP-1 treatment is now embedded in federal healthcare policy.As access expands, consumer behavior shifts.Clinical guidance for GLP-1 patients
More news about: MENU - ORDER AI
Mar 03, 2026, 09:04 ET CenExel Clinical Research Network Expands Capabilities Across Sites Nationwide
investigators to support metabolic and general health studies.Additionally, a board-certified obesity medicine specialist has joined the team to lead GLP/GIP and metabolic-focused research initiatives, further strengthening the network's metabolic research portfolio.Atlanta, GeorgiaCenExel's
More news about: CenExel Clinical Research
Mar 03, 2026, 08:46 ET Clean Eatz Kitchen Launches Subscription-Free GLP-1 Meal Plan for Ozempic®, Wegovy®, and Mounjaro® Users
food."The GLP-1 Meal Plan is available now at cleaneatzkitchen.com/products/glp-1-meal-plan-delivery. The company has also published an independent comparison of GLP-1 meal delivery services at cleaneatzkitchen.com/pages/best-meal-delivery-for-glp1 and a comprehensive GLP-1 nutrition
More news about: CE Kitchen Inc
Mar 03, 2026, 08:00 ET Dario Uniquely Positioned to Amplify the Impact of Oral GLP-1 Therapies Through Precision Behavioral Support: 79% of Members Already Using Dario's Weight Management
As oral GLP-1s enter the market with slightly more modest weight and glycemic outcomes than injectable formulations, Dario integrates structured behavioral reinforcement to optimize real-world successGiven GLP-1 medication expense is one
More news about: DarioHealth Corp.
Mar 03, 2026, 08:00 ET League Spring '26 Release: The New Frontier for Orchestrated AI Care Navigation and Care Gap Closure
advancing live deployments of AI-enabled journey capabilities across leading retail pharmacy and payer organizations:GLP-1 Journey Goals: A specialized program for high-cost medication support goes live this month within a leading North American retail pharmacy and
More news about: League Inc.
Mar 03, 2026, 07:00 ET Brevel's Illuminated Fermentation Brings Pure Chlorella to the Nutraceutical Space
strategic nutritional tool for filling protein and nutrient gaps in GLP-1 and other reduced-calorie diets where users must be sure they are getting more from every bite they consume. We call it GLP-1 friendly food."Brevel Purallis™ is readily incorporated into functional
More news about: Brevel, Ltd.
Mar 03, 2026, 00:48 ET Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
through multiple targets:enhancing glucose-stimulated insulin secretion from pancreatic β-cells,promoting GLP-1 release from intestinal L-cells, andmodulating hepatic glucose output through glycogen regulation.This coordinated, multi-organ
More news about: Hua Medicine
Mar 02, 2026, 13:03 ET New York Healthcare Entrepreneur Bracha Banayan Launches Hello Dose Telehealth Platform for Clinician-Supervised GLP-1 Weight Management Care, Introducing the DROP™ Method Framework
Hello Dose introduces the DROP™ Method, a structured four-step framework designed to support clinician-supervised GLP-1 medication management with behavioral and educational guidance.NEW YORK, March 2, 2026
More news about: Hello Dose.
Mar 02, 2026, 13:03 ET Sales at record high, Americans view meat as part of a healthy, balanced lifestyle
health and nutrition perceptions, with 77% of shoppers agreeing that meat and poultry are part of a healthy diet, up more than 20% since 2020. GLP-1 users over-index versus non-users for eating somewhat or a lot more meat than last year (161) and for frequently including meat and poultry in snacking
More news about: North American Meat Institute